RoosterBio Headquarters in Frederick, MD
Our team has been working diligently this year to grow our customer base across the globe, now shipping to 26 countries and the need to expand our facility is a result of the industry validating our value proposition.
FREDERICK, Md. (PRWEB)
December 18, 2019
RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems, announces today an expansion of its facility in Frederick, Maryland for the second time in 2019. The addition of 5,000 square feet to its existing 15,500 footprint supports the company’s expansion efforts and provides infrastructure to meet a growing international demand for its standardized hMSC bioprocess tools. By strengthening its cell manufacturing solution portfolio and presence in the Asia Pacific and Europe, RoosterBio is giving more people around the world the ability to advance regenerative medicine cures.
RoosterBio’s headquarters at The Offices at Westview serves as a center of excellence, incorporating the latest scale up bioprocessing technology and allows the company to quality test its cells and media in a variety of conditions and applications. The new space will increase shipping capabilities for a growing international network by the end of the year. RoosterBio announced the first expansion of its facility earlier this year which served as a catalyst for its strategic international growth initiatives. The company plans to launch an international presence in Asia during the first half of 2020.
“Our team has been working diligently this year to grow our customer base across the globe, now shipping to 26 countries and the need to expand our facility is a result of the industry validating our value proposition,” said RoosterBio’s Chief Executive Officer Margot Connor. “As our efforts have increased, we’ve increased our employee base by nearly 30% this year and we’re excited about our continued annual growth rate.” Connor added, “We’re taking RoosterBio to the next level in the international hMSC marketplace.”
These enhancements build on RoosterBio’s proven track record of industrializing the supply chain for the new field of regenerative medicine. The products that RoosterBio has commercialized are designed to standardize hMSC manufacturing with consistent cGMP product offerings, removing years of time, and millions of dollars, from traditional mesenchymal cell therapeutic product development and clinical translation efforts. RoosterBio will also be launching a cGMP version of its extracellular vesicle production tools in early 2020.
About RoosterBio, Inc
RoosterBio, Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio’s products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio’s innovative products are ushering in a new era of productivity and standardization to the field, accelerating the road to discovery in Regenerative Medicine. For more information on RoosterBio, please visit http://www.roosterbio.com.
Share article on social media or email: